Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.91 |
| ▸ | BLM | P54132 | 1/20 | 0.91 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.91 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | INPPL1 | O15357 | 2/20 | 0.35 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | INPP5B | P32019 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.35 |
| ▸ | ITPR3 | Q14573 | 3/20 | 0.33 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.33 |
| ▸ | ITPR2 | Q14571 | 1/20 | 0.33 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL292348 | 0.95 | FDPS (1.00) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL29634664 | 0.95 | — | — | |
| Pyrophosphoric Acid SCHEMBL8851914 | 0.95 | FDPS (1.00) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL3654 | 0.95 | — | — | |
| Pyrophosphoric Acid SCHEMBL23537746 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL396637 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL714818 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL21433694 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL21145230 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 | |
| Pyrophosphoric Acid SCHEMBL11171410 | 0.91 | FDPS (0.91) | FDPSBLMTDP1CA4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067964-B2 | Complex and method for enhancing nuclear delivery | OLIGOMER SCIENCES AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20110306138-A1 | COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | OLIGOMER SCIENCES AB (SE) | 2011-12-15 | — | — | US | disclosed |
| EP-2376518-A1 | A COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | Avaris AB (SE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071587-A1 | A COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | AVARIS AB (SE) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306138-A1 | COMPLEX AND METHOD FOR ENHANCING NUCLEAR DELIVERY | SNRPE, SNRPA, HNRNPH3 | FDPS 4137/4885BLM 3298/4885TDP1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.